Systemically administered allogeneic mesenchymal stem cells do not aggravate the progression of precancerous lesions: a new biosafety insight

Stem Cell Research & Therapy
Flavia BrunaPaulette Conget

Abstract

Mesenchymal stem cells (MSCs) are a heterogeneous subset of stromal cells currently tested for multiple therapeutic purposes. Their potential to home into tumors, to secrete trophic/vasculogenic factors, and to suppress immune response raises questions regarding their biosafety. Our aim was to evaluate whether systemically administered allogeneic MSCs modify the natural progression of precancerous lesions and whether their putative effect depends on cancer stage and/or cell dose. Oral squamous cell carcinoma (OSCC) was induced in Syrian golden hamsters by topical application of 7,12-dimethylbenz[a]anthracene in one buccal pouch. At hyperplasia, dysplasia, or papilloma stage, animals received intracardially the vehicle or 0.7 × 106, 7 × 106, or 21 × 106 allogeneic bone marrow-derived MSCs/kg. OSCC progression was assessed according to the presence of erythroplakia and leukoplakia, extent of inflammation and vascularization, and appearance, volume, and staging of tumors. Also, the homing of donor cells was studied. Precancerous lesions progressed from hyperplasia to dysplasia in 2 weeks, from dysplasia to papilloma in 3 weeks, and from papilloma to carcinoma in 4 weeks. This time course was unmodified by the systemic administrati...Continue Reading

References

Jan 1, 1988·Nutrition and Cancer·J SchwartzD Trickler
Aug 24, 1999·Journal of Cellular Physiology·P A Conget, J J Minguell
Apr 19, 2006·Journal of Cellular Biochemistry·Arnold I Caplan, James E Dennis
Apr 25, 2006·Experimental Cell Research·Ida Rasmusson
Oct 25, 2006·Transplantation·Farida DjouadDanièle Noël
Nov 6, 2007·Journal of Cellular and Molecular Medicine·Stephen G BallCay M Kielty
Sep 12, 2008·Nature Reviews. Cancer·Jane E Visvader, Geoffrey J Lindeman
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Fernando EzquerPaulette Conget
Apr 13, 2010·Stem Cells and Development·Araceli Valle-Prieto, Paulette A Conget
Jul 14, 2010·Cell Stem Cell·Patrick L TaylorIrving L Weissman
Aug 26, 2010·Cytotherapy·Darwin J ProckopArmand Keating
Jan 1, 2008·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Philippe BourinLuc Sensebé
Feb 27, 2013·The American Journal of Pathology·Jung S Byun, Kevin Gardner
Mar 31, 2015·World Journal of Stem Cells·Martha L Arango-RodriguezPaulette Conget
Apr 14, 2016·British Journal of Hospital Medicine·Anne M Hegarty, Keith D Hunter
Jun 9, 2016·Expert Opinion on Biological Therapy·Anna HagenhoffPeter J Nelson
Nov 24, 2016·Alimentary Pharmacology & Therapeutics·C GrégoireY Beguin
Jan 16, 2018·International Journal of Medical Sciences·Vladislav VolarevicMiodrag Stojkovic

❮ Previous
Next ❯

Citations

May 22, 2019·International Journal of Molecular Sciences·Benjamin BochonGrzegorz Wystrychowski

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Software Mentioned

StatGraph Prism

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.